AEON
AEON Biopharma, Inc.
NYSE American · usd
AEON Biopharma, Inc. (AEON) trades at $0.1230 (-7.59%) as of 8:00:00 PM EST on Nov 20, 2026, -47.37% over the past month. Market cap is $11.2M, with 6.4 days to cover in short interest.
Stock performance
How AEON Biopharma, Inc. (AEON) stock has performed from one day to one year, with its 52-week range.
- 1D
- -7.59%
- 1W
- -19.61%
- 1M
- -47.37%
- YTD
- -88.82%
- 1Y
- -85.18%
- 52-wk range
- $0.11 – $1.45
Key statistics
Today's trading snapshot for AEON: day range, open, previous close, volume and market cap.
- Day range
- $0.12 – $0.13
- Open
- $0.13
- Prev close
- $0.13
- Volume
- 1.17M
- Market cap
- $11.2M
- Shares out
- 71.52M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for AEON Biopharma, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 4.58
- P/FCF
- —
- ROE
- -1995.8%
- ROA
- -337.0%
- Debt/Equity
- 1.21
- Div yield
- 0.00%
As of Nov 19, 2026
8-K filings
Material corporate events AEON Biopharma, Inc. has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 16, 2026
On November 16, 2026, AEON Biopharma, Inc. (the "Company" or "AEON") announced financial results for the third quarter ended September 30, 2026.
- Regulatory decisionNov 3, 2026
On September 30, 2026, the Company publicly announced that it had received Type 2b meeting minutes from the U.S. Food and Drug Administration that did not preclude advancement of ABP-450 toward a Biologics License Application under the Section 351(k) biosimilar pathway, thereby triggering the accelerated expiration of the Two-Year Warrants in accordance with their terms.
- Investor presentationOct 23, 2026
On October 23, 2026, AEON Biopharma, Inc. made available in the investor relations section of its website a presentation (the "Corporate Presentation"), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
- Regulatory decisionSep 30, 2026
The FDA agreed in principle with the Company's proposed two-stage design for a comparative pharmacodynamic study using Compound Muscle Action Potential ("CMAP") measurement in the extensor digitorum brevis muscle, consisting of an initial dose-finding stage followed by a comparative pharmacodynamic evaluation. The FDA provided recommendations intended to strengthen the study's ability to demonstrate assay sensitivity.
- Listing compliance regainedAug 3, 2026
On August 3, 2026, the Company received a letter from NYSE Regulation confirming that the Company has regained compliance with the continued listing standards of NYSE American. The letter stated that the Company is in compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide.
Dividend history and stock splits
AEON Biopharma, Inc.'s recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-72Feb 26, 2025
AEON short interest
How heavily AEON is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 6.4
- Short interest
- 2.66M
- Avg volume
- 415.78K
As of · reported to FINRA twice monthly.
AEON news
The latest news and headlines about AEON Biopharma, Inc. (AEON).
- Bitget Launchpool adds AEON (AEON) with 1.1M in Token RewardspositiveGlobeNewswire Inc.· Jul 27, 2026
- AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache SocietypositiveGlobeNewswire Inc.· Jun 4, 2026
- AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711neutralGlobeNewswire Inc.· Apr 3, 2026
- AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711neutralGlobeNewswire Inc.· Dec 19, 2025
- Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsightneutralGlobeNewswire Inc.· Dec 2, 2025
Frequently asked questions
What is the AEON Biopharma, Inc. (AEON) stock price today?
AEON Biopharma, Inc. (AEON) is trading at $0.1230 (-7.59% on the day) as of 8:00:00 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is AEON Biopharma, Inc.?
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications.
What is the short interest in AEON?
As of Oct 30, 2026, AEON has 2.66M shares short and 6.4 days to cover.
What exchange is AEON listed on?
AEON Biopharma, Inc. (AEON) trades on NYSE American in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of AEON with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a AEON analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.